Updated duration of response for patients receiving dostarlimab plus carboplatin-paclitaxel treatment compared with patients receiving placebo plus carboplatin-paclitaxel in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial.
Saved in:
| Title: | Updated duration of response for patients receiving dostarlimab plus carboplatin-paclitaxel treatment compared with patients receiving placebo plus carboplatin-paclitaxel in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. |
|---|---|
| Authors: | Mirza, Mansoor1,2 (AUTHOR), Willmott, Lyndsay3 (AUTHOR), Hietanen, Sakari4 (AUTHOR), Gilbert, Lucy5 (AUTHOR), Myers, Tashanna6 (AUTHOR), Balázs, Boglárka7 (AUTHOR), Pennington, Kathryn8 (AUTHOR), Bauerschlag, Dirk9 (AUTHOR), Miller, Eirwen10 (AUTHOR), Boere, Ingrid11 (AUTHOR), Buttin, Barbara12 (AUTHOR), Edelson, Mitchell13 (AUTHOR), Boone, Jonathan14 (AUTHOR), Powell, Matthew15 (AUTHOR), Diaz, John16 (AUTHOR), Holloway, Robert17 (AUTHOR), Grimshaw, Matthew18 (AUTHOR), Austin, Laura19 (AUTHOR), Valabrega, Giorgio20,21 (AUTHOR), Buscema, Joseph22 (AUTHOR) |
| Source: | Gynecologic Oncology. 2025 Supplement 1, Vol. 200, p87-87. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
